Free Trial
OTCMKTS:DDXS

Diadexus (DDXS) Stock Price, News & Analysis

Diadexus logo

About Diadexus Stock (OTCMKTS:DDXS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
30 shs
Average Volume
15,481 shs
Market Capitalization
$53,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

Receive DDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diadexus and its competitors with MarketBeat's FREE daily newsletter.

DDXS Stock News Headlines

DDXSQ Historical Data
Truen Co Ltd (417790)
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Diadexus, Inc. to File Chapter 7
See More Headlines

DDXS Stock Analysis - Frequently Asked Questions

Diadexus, Inc. (OTCMKTS:DDXS) posted its quarterly earnings data on Monday, October, 26th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.35.

Shares of DDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diadexus investors own include GoPro (GPRO), GE Aerospace (GE), Ambarella (AMBA) and Alliqua Biomedical (ALQA).

Company Calendar

Last Earnings
10/26/2015
Today
5/20/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
Business Services
Current Symbol
OTCMKTS:DDXS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$53,000.00
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:DDXS) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners